Abstract
Fusions in the ROS1 proto-oncogene are among the best treatable genetic aberrations in Non-small cell lung cancer (NSCLC). Besides the occurrence of solvent-front mutations (SFM) in acquired resistance to targeted therapy, little is known about small-scale ROS1 aberrations. We comprehensively analyzed clinical and molecular characteristics of ROS1 mutations in NSCLC patients without activating ROS1 fusions or SFMs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have